Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Centessa Pharmaceuticals Plc ADR (CNTA)
Centessa Pharmaceuticals Plc ADR (CNTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,049,512
  • Shares Outstanding, K 97,629
  • Annual Sales, $ 0 K
  • Annual Income, $ -216,210 K
  • 60-Month Beta 1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.00
Trade CNTA with:

Options Overview Details

View History
  • Implied Volatility 119.57% ( +4.92%)
  • Historical Volatility 92.19%
  • IV Percentile 88%
  • IV Rank 67.29%
  • IV High 173.58% on 01/23/24
  • IV Low 8.47% on 12/19/23
  • Put/Call Vol Ratio 0.05
  • Today's Volume 22
  • Volume Avg (30-Day) 39
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 421
  • Open Int (30-Day) 290

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.44
  • Number of Estimates 3
  • High Estimate -0.38
  • Low Estimate -0.50
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +2.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.38 +49.19%
on 02/08/24
11.95 -7.87%
on 02/20/24
+2.97 (+36.94%)
since 01/23/24
3-Month
5.58 +97.21%
on 12/01/23
11.95 -7.87%
on 02/20/24
+4.47 (+68.35%)
since 11/22/23
52-Week
3.03 +263.37%
on 03/01/23
11.95 -7.87%
on 02/20/24
+7.64 (+226.71%)
since 02/23/23

Most Recent Stories

More News
Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

/PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon...

CNTA : 11.01 (+2.42%)
CLVT : 8.99 (+0.33%)
Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?

Centessa Pharmaceuticals (CNTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CNTA : 11.01 (+2.42%)
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Centessa...

CNTA : 11.01 (+2.42%)
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Centessa Pharmaceuticals plc (CNTA) Investors of Class Action Deadline and Encourages Investors to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ:...

CNTA : 11.01 (+2.42%)
CENTESSA PHARMACEUTICALS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 28, 2022 to file lead plaintiff applications...

CNTA : 11.01 (+2.42%)
CENTESSA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Centessa Pharmaceuticals Plc (“Centessa” or the...

CNTA : 11.01 (+2.42%)
CNTA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 28, 2022 in the Class Action Filed on Behalf of Centessa Pharmaceuticals plc Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Centessa Pharmaceuticals plc (NASDAQ:...

CNTA : 11.01 (+2.42%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline - CNTA

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc ("Centessa" or the "Company") (NASDAQ:...

CNTA : 11.01 (+2.42%)
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Centessa Investors of a Lead Plaintiff Deadline of November 28, 2022

/PRNewswire/ -- Attention Centessa Pharmaceuticals plc ("Centessa") (NASDAQ: CNTA) shareholders: The Law Offices of Vincent Wong announce that a class action...

CNTA : 11.01 (+2.42%)
CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA

/PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 28, 2022 to file lead plaintiff...

CNTA : 11.01 (+2.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 12.09
2nd Resistance Point 11.63
1st Resistance Point 11.32
Last Price 11.01
1st Support Level 10.56
2nd Support Level 10.10
3rd Support Level 9.79

See More

52-Week High 11.95
Last Price 11.01
Fibonacci 61.8% 8.54
Fibonacci 50% 7.49
Fibonacci 38.2% 6.44
52-Week Low 3.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar